Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7669-7674

  D'Amato, Robert ^a,d   Becker, Christian M ^a,c   Prox, Daniela ^a   Fannon, Michael ^a   Flynn, Evelyn ^a   Fogler, William E ^e   Sim, B Kim Lee ^e   Allred, Elizabeth N ^a   Kisker, Oliver ^a,b   Folkman, Judah ^a,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ENTREMED INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; CANCER CELL; CANCER MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FIBROSARCOMA; HUMAN; HUMAN CELL; IMPLANTATION; LUNG CARCINOMA; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; OSMOTIC PUMP; PANCREAS CANCER; PRIORITY JOURNAL; SCID MOUSE; TREATMENT OUTCOME; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; COLLAGEN; DRUG STABILITY; ENDOSTATINS; FIBROSARCOMA; HUMANS; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, PARENTERAL; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED CBA; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; OSMOTIC PRESSURE; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035887379     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
3. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma
4. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
5. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
6. Endostatin. Yeast production, mutants, and antitumor effect in renal cell carcinoma
7. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
8. Inhibitory effect of full-length human endostatin on in vitro angiogenesis
9. Cloning, expression, and in vitro activity of human endostatin
10. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
11. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
12. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors
13. Zinc ligand-disrupted recombinant human endostatin: Potent inhibitor of tumor growth, safety and pharmacokinetic profile
14. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth
15. Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastases in rats
16. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
17. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
18. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
19. Angiostatin induces and sustains dormancy of human primary tumors in mice
20. Effect of antiangiogenic therapy on slow-growing, poorly vascularized tumors in mice
21. Angiogenesis-dependent diseases